Lack of muco-cutaneous signs of toxic shock syndrome when t cells are absent: S. aureus shock in immunodeficient adults with multiple myeloma

Clinical and Experimental Immunology

Volumn 128, Issue 1, 2002, Pages 131-139

  Kamel, N S ^a   Banks, M C ^a   Dosik, A ^a   Ursea, D ^a   Yarilina, A A ^a,b   Posnett, D N ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

Immunodeficiency; Multiple myeloma; Staphylococcus aureus; Superantigen; Toxic shock syndrome

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; M PROTEIN; MELPHALAN; RECOMBINANT ERYTHROPOIETIN; STAPHYLOCOCCUS TOXIN; STEROID; SUPERANTIGEN; THALIDOMIDE;

ADRENAL INSUFFICIENCY; ADULT; ANTIBIOTIC THERAPY; ANTIGEN FUNCTION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; CHEMOTHERAPY; CHILD; CLINICAL EXAMINATION; COLON PERFORATION; CONGESTIVE HEART FAILURE; DESQUAMATION; DRUG MEGADOSE; ERYTHRODERMA; FEMALE; HEMODIALYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPEREMIA; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; KIDNEY FAILURE; LYMPHOCYTE PROLIFERATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOSA; MULTIPLE MYELOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPSIS; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; STEROID THERAPY; T LYMPHOCYTE SUBPOPULATION; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME;

ADULT; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, T-CELL RECEPTOR; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MUCOUS MEMBRANE; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTIONS; SHOCK, SEPTIC; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 0036243131     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01805.x     Document Type: Article

References (43)

1. Case definitions for public health surveillance. Toxic shock syndrome
2. Toxic shock syndrome in the United States: Surveillance update, 1979-1996
3. Active surveillance for Toxic Shock Syndrome in the United States, 1986
4. Infections in immunocompromised patients
5. Epidemiology of community-acquired Infection
6. Toxic shock syndrome
7. Taxonomy and sytematics of staphylococci indigenous to humans
8. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin
9. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: Implications for toxic-shock syndrome
10. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS
11. Evolving superantigens of Staphylococcus aureus
12. Bacteremic non-menstrual Staphylococcal Toxic Shock Syndrome associated with enterotoxins A and C
13. Superantigens in human disease
14. Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes
15. Involvment of enterotoxins G and I in staphylococcal toxic shock syndrome and staphylococcal scarlet fever
16. Immunological factors and risk of infection in plateau phase myeloma
17. Infection in myeloma
18. Differentiation of human CD8 T cells: Implications for in vivo persistence of oligoclonal CD8+28- cytotoxic effector clones
19. Vβ-specific stimulation of human T cells by staphylococcal toxins
20. Characterization of human T cells reactive with the mycoplasma arthritidis-derived superantigen (MAM): Generation of a monoclonal antibody against Vβ17, the T cell receptor product expressed by a large fraction of MAM-reactive human T cells
21. Selective expansion of T cells expressing Vβ2 in toxic shock syndrome
22. The acquired immunodeficiency syndrome and nonmenstrual toxic shock syndrome
23. Toxic shock syndrome as the AIDS-defining diagnosis
24. The human immunodeficiency virus and non-menstrual toxic shock syndrome: A female case presentation
25. Staphylococcal toxic shock syndrome associated with human immunodeficiency virus infection: Report of a case with bacteremia
26. Nonmenstrual toxic shock syndrome in a young child with human immunodeficiency virus infection
27. Toxic shock syndrome in AIDS
28. Toxic shock syndrome without rash in a young child: Link with syndrome of hemorrhagic shock and encephalopathy
29. Toxic Shock Syndrome. Are you recognizing its changing presentations?
30. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): Comparison with menstrual TSS by multivariate discriminant analyses
31. Engagement of major histocompatibility complex class II molecules by superantigen induces inflammatory cytokine gene expression in human rheumatoid fibrob-last-like synoviocytes
32. Staphylococcal super-antigens as inducers of signal transduction in MHC class II-positive cells
33. Menstrual toxic shock syndrome complicated by persistent bacteremia: Case report and review
34. Structure and function of streptococcal and staphylococcal superantigens in septic shock
35. Role of substance P in immediate-type skin reactions induced by staphylococcal enterotoxin B in unsensitized monkeys
36. Neuropeptides and the immune system: Substance P receptors on the bronchus associated lymphoid tissue of rats
37. Cytokines modulate terminal differentiation and the expression of predesquamin in cultured keratinocytes
38. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: Case report and review
39. Intravenous immunoglob-ulin therapy for streptococcal toxic shock syndrome - A comparative observational study. The Canadian Streptococcal Study Group
40. Varying titers of neutralizing antibodies to streptococcal super-antigens in different preparations of normal polyspecific immunoglob-ulin G: Implications for therapeutic efficacy
41. Cross-reactive antibodies prevent the lethal effects ofStaphylococcus aureus superantigens
42. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens